TF and cancer: In the univariate analysis, low transferrin was associated with shorter relapse‐free survival (RFS) (hazard ratio [HR] 2.180, 95% confidence interval [CI] 1.417‐3.354, P < .001), overall survival (OS) (HR 2.930, 95% CI 1.784‐4.811, P < .001), and cancer‐specific survival (CSS) (HR 2.122, 95% CI 1.053‐4.275, P = .035).